Is the GSK share price the bargain of the year?

Plans for a break-up could be just what the doctor ordered for pharma group GlaxoSmithKline plc (LON:GSK), says Roland Head.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE 100 pharma giant GlaxoSmithKline (LSE: GSK) is heading for a break-up. Chief executive Emma Walmsley will oversee the creation of two companies — a focused and faster-growing pharmaceutical company and a profitable, stable consumer healthcare business.

This strategy isn’t a sure thing, but I think there’s a good chance it will work. Today I’ll explain why. I’ll also take a look a FTSE 250 stock which I think offers an interesting mix of opportunity and risk.

A break-up makes sense

In the past I’ve been a supporter of Glaxo’s conglomerate structure. This combines mature consumer products such as Panadol, Nicorette and Sensodyne with cancer treatments and other pharmaceuticals.

But this hasn’t worked out well. The group’s performance has stagnated for years and its shares have lagged the FTSE 100. In the meantime, debt levels have risen.

After less than two years in the job, Ms Walmsley has secured a deal to merge the firm’s consumer healthcare business with that of US pharma rival Pfizer. The resulting joint venture is expected to become a standalone business within three years.

One big advantage for Glaxo shareholders is that a sizeable part of the group’s £22bn net debt is likely to be carved out into the new consumer business. This will leave the pharmaceutical business with a stronger balance sheet and more flexibility to invest in new growth opportunities.

Too good to be true?

You could argue that this is all just financial engineering, designed to disguise the fact that Glaxo has too much debt and is due for a dividend cut.

The reality is that we won’t know how well the split will work for another few years.

In the meantime, I’m happy to give Ms Walmsley the benefit of the doubt. Although I don’t think that GlaxoSmithKline is the bargain of the year, I do think that the group’s 5.3% dividend yield remains attractive for income investors.

How will this story end?

FTSE 250 cinema chain Cineworld Group (LSE: CINE) has been one of the stock market success stories of recent years. The firm’s shares have risen by 118% in five years and are up by 6% at the time of writing.

The twist in this story is that Cineworld splashed out $5.8bn on the acquisition of US rival Regal Entertainment last year. This has transformed the UK firm into the second-largest cinema chain in the world.

Results published today show that the combined group’s revenue rose by 7.2% to $4,711m last year, while its adjusted EBITDA (earnings before interest, tax, depreciation and amortisation) rose by 9.4% to $1,0722m. Both figures are calculated as though the two companies had always been combined.

This ambitious acquisition is expected to generate cost savings of $150m in 2019. But this deal has also left Cineworld with net debts totalling $3.9bn. That’s equivalent to about 3.7 times adjusted EBITDA. That’s well above my preferred maximum of 2x EBITDA.

Today’s numbers suggest to me that reducing debt to a more comfortable level could take three to five years. In my view, a dividend cut would be prudent to speed up this process. Instead, the 2018 payout will be lifted by 15%.

Cineworld shares now trade on about 12.5 times 2019 earnings, with a forecast yield of 4.6%. Given the group’s debt level, I’d say the shares look fully valued. I’d hold.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »